Context Therapeutics Exciting Presentation at Major Oncology Conference
Context Therapeutics Inc. (Nasdaq: CNTX), a leading clinical-stage biopharmaceutical firm, is set to showcase groundbreaking research at the American Association for Cancer Research Annual Meeting. The conference will be held from April 25 to April 30, 2025, and is anticipated to gather oncologists, researchers, and industry leaders to discuss advancements in cancer therapeutics.
Highlighting CT-95 at the AACR Annual Meeting
A poster presentation will focus on Context Therapeutics' clinical asset, CT-95, a T cell engaging bispecific antibody targeting mesothelin (MSLN). This presentation uniquely emphasizes the determination of a first-in-human dose of CT-95, utilizing the minimal anticipated biological effect level (MABEL) as an essential framework for immune agonist drugs. Context's rigor in this innovative approach indicates their commitment to safety and efficacy in cancer treatment.
What is CT-95?
CT-95 is designed to redirect T cell-mediated lysis towards malignant cells that express the mesothelin protein. This protein is known for being overexpressed in approximately 30% of various cancers, making it a critical target for therapeutic strategies. However, the road to developing effective MSLN-targeted therapies has been challenged by the presence of shed or soluble mesothelin in both blood and the tumor microenvironment, acting as a decoy for therapeutic antibodies. CT-95 is a fully humanized bispecific T cell engager that aims to mitigate this issue with a balance of moderate affinity and high avidity for membrane-bound MSLN.
Details of the Poster Presentation
The poster presentation is scheduled for Monday, April 28, 2025, from 9:00 a.m. to 12:00 p.m. CT. Attendees can expect to learn about the specifics regarding the title of the poster, which is - "Determination of First in Human Dose of the T Cell-Redirecting Bispecific Antibody CT-95 Targeting Mesothelin." Additionally, the abstract number for this significant work is 2139, and it will be showcased during a session focused on Clinical Research under the category of Therapeutic Antibodies, including engineered options.
Company Vision and Future Research
Context Therapeutics is not only dedicated to CT-95 but is also expanding its portfolio to include innovative T cell engaging bispecific therapeutics. The company's pipeline consists of multiple promising candidates, such as CTIM-76 and CT-202, targeting Claudin 6 and Nectin-4, respectively. This diverse portfolio positions Context Therapeutics as a significant player in the field of oncology, aiming to provide novel solutions that revolutionize cancer treatment.
About Context Therapeutics
Context Therapeutics Inc. (Nasdaq: CNTX) is headquartered in Philadelphia and focuses on advancing T cell engaging bispecific antibodies for solid tumors. The company is driven by a mission to develop transformative therapies that address the limitations of current cancer treatments. For more information on their initiatives, products, and research breakthroughs, please visit their official website.
Frequently Asked Questions
What is the purpose of the CT-95 presentation at AACR?
The presentation aims to share vital data regarding the first-in-human dose determination of CT-95, promoting safety and efficacy for future clinical applications.
When is the AACR Annual Meeting taking place?
The AACR Annual Meeting is scheduled for April 25-30, 2025, providing a platform for cancer research discussions.
What does CT-95 target?
CT-95 targets mesothelin (MSLN), which is overexpressed in many cancers, thus enabling the redirection of T cells to attack malignant cells effectively.
What is the significance of MABEL in this research?
MABEL, or minimal anticipated biological effect level, is used to determine the optimal starting dose for CT-95, ensuring safety for patients in clinical trials.
How can we learn more about Context Therapeutics?
For further details on their research, products, and updates, you can visit Context Therapeutics' official website or follow their social media channels.
